Answers are grounded in this paper and cite their sources.
Background and Objectives: Safety and tolerability of atomoxetine were studied in the largest double-blind, placebo-controlled, randomised withdrawal trial of atomoxetine (80 or 100 mg/day) in adults with attention-deficit/hyperactivity disorder (ADHD).
No takes yet. Share an insight, caveat, or question.
Camporeale et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: